Tech Company Financing Transactions

Breye Therapeutics Funding Round

Mission BioCapital, Novo Holdings and EIFO participated in a $76.5 million Series A venture round for Breye Therapeutics. The financing round was announced on 9/29/2026.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
Denmark, SC Undisclosed
USA

Phone

Undisclosed

Website

www.breyetx.com

Email Address

Undisclosed

Overview

Breye Therapeutics is a clinical stage clinical biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye has two novel and relevant small molecule oral therapies to address large unmet medical needs in both diabetic retinopathy (DR) and age-related macular degeneration (AMD)

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ulrik Mouritzen

        

Browse more venture capital transactions:

Prev: 9/29/2026: ai3Bio venture capital transaction
Next: 9/29/2026: ITpipes venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary